Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

SpeedWeed

AUGUST 16, 2021

LAS VEGAS, NV [August 16, 2021] – Cannabis Conference , produced by parent company GIE Media Inc. 24-26, 2021, at Paris Las Vegas Hotel & Casino. We couldn’t be more thrilled to host Dr. Sisley at Cannabis Conference 2021 as our Day 2 keynote,” said Cannabis Conference Programming Director Cassie Neiden Tomaselli. “Dr.

Media 52

Media Clinical Trials DEA Hemp 52

Cannabis Law Report

SEPTEMBER 9, 2021

Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event. The live and archived webcast will be available for 90 days after the event.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. 17 Aug 2021. Fletcher S. Child: care, health and development. See the Answer.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

OCTOBER 28, 2021

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc.

Data 52

Data Clinical Trials Events Medicine 52

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Actual results and future events could differ materially from those anticipated in such information.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

JUNE 17, 2021

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Brains” or the “Company”) is pleased to announce the completion of a USD $31.9

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

OCTOBER 5, 2021

Investors can register for the event here and view the live presentation here. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Management will deliver a company presentation on October 15 th at 3:25 p.m.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

JUNE 7, 2021

Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S. Food and Drug Administration (U.S.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

OCTOBER 15, 2021

Xebra’s 125,619,492 issued and outstanding common shares will commence trading at market open on Monday, October 18, 2021 under the ticker symbol “ XBRA “. Planting of the first trial crop is expected to commence in December 2021 , which will be harvested and submitted to the Dutch government in March 2022. THE NETHERLANDS.

Seed-To-Sale 52

Seed-To-Sale Cultivation Clinical Trials Cannabinoids 52

Cannabis Law Report

JUNE 4, 2021

– Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Presenter: Dr. Scott Tagawa MD, MS, FACP.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JULY 29, 2021

VANCOUVER, BC , July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

OCTOBER 15, 2021

RespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness. PAOG expects to realize its first CBD nutraceutical product sales beginning imminently in Q4, 2021. USOTC: USMJ).

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

AUGUST 24, 2021

A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JUNE 14, 2022

There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. The partnership will be officially launched at the virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies taking place on 23rd June, 14:00 – 16:00 CEST.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 9, 2021

Thu, December 9, 2021, . 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”). the CBD, CBG or THC compounds).

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JUNE 7, 2021

A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

OCTOBER 5, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. The Company’s presentation will be available for viewing that day at 10:10 a.m.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. Brett Maas.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

SEPTEMBER 2, 2021

Testing is scheduled to begin in the second half of September 2021. The College, part of the State University of New York (SUNY) system, is aligned with SUNY’s vaccination mandate, which requires all on-campus students to be fully vaccinated against COVID-19 by September 27, 2021. Hayward, president and CEO of Applied DNA. “As

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

AUGUST 3, 2021

– Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs’ safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening –. Fiscal 2021 Third Quarter Financial Results and Investor Conference Call. Food and Drug Administration (U.S.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 1, 2021

Launched in summer 2021 with a generous grant from the Saisei Foundation, the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. Background. The Role of Psychedelics in Healing Trauma.

Law 59

Law Policy Research and Development Clinical Trials 59